Clinical Sites

Our clinical study sites are unique, robust, and relevant in the following ways:

• Geographic diversity: We are connected to sites in South Asia, Southeast Asia, Eastern Europe, Southern Africa, Eastern Africa, Western Africa and South America.

• Representation across different TB epidemics: We work in countries with high TB burden, high HIV/TB burden, high MDR TB burden, and/or high (>5%) diabetes prevalence. Our network facilitates evaluation of novel TB diagnostics in the specific target population(s) needed for further development of a particular test: adults and children with TB symptoms, high-risk groups for whom systematic TB screening is recommended (PLHIV, people living with diabetes, prisoners), and patients with advanced drug resistance phenotypes.

• Access to key markets for scale-up of novel TB diagnostics: We work in three BRICS countries and two additional countries that are ranked among the top 20 in the world based on population and the absolute number of TB cases